Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
OpenAI Nears Astra AI Model Launch With Safety Focus 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Xiaomi Shares Jump on Europe EV Expansion Plan 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Milei Threatens Falkland Oil Firms With Sanctions 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
France Targets Shein, Temu With Fast-Fashion Fees 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Add as a preferred source on Google
Heidelberg, Germany, March 8, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at the Cowen and Company 38th Annual Health Care Conference on Wednesday, March 14, 2018 at 10:00 am ET.
A live webcast of the conference presentation can be accessed through the "Events" section on the "Investors & Media" page of the Affimed website at www.affimed.com/events.php. A replay of the presentation will be available from Affimed's website for 30 days following the conference.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected], [email protected]
